Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 12 of 12 matching drugs for CHRNB4 — including drugs targeting any of its 16 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells CHRNB4 Direct 2
ethanol, enoxaparin CHRNB4 Direct 1
mecamylamine CHRNB4 Direct yes 0
mecamylamine hydrochloride CHRNB4 Direct yes 0
pentolinium CHRNB4 Direct yes 0
pentolinium tartrate CHRNB4 Direct yes 0
trimethaphan CHRNB4 Direct yes 0
trimethaphan camsylate CHRNB4 Direct yes 0
biopsy, biospecimen collection, ceralasertib, computed tomography, echocardiography, multigated acquisition scan, positron emission tomography, trastuzumab deruxtecan ATR SSL via ATR 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin TP53 SSL via TP53 1
ceralasertib, olaparib, durvalumab ATR SSL via ATR 1
cisplatin, carboplatin, etoposide, durvalumab, ceralasertib ATR SSL via ATR 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.